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potentially be used to individualize treatment selection between
lisdexamfetamine dimesylate (LDX) and osmotic-release oral system
methylphenidate (OROS-MPH) in children and adolescents with atten-
tion deﬁcit/hyperactivity disorder (ADHD). Methods: The study used
data from patients with ADHD receiving LDX (N ¼ 104) or OROS-MPH
(N ¼ 107) in a phase III randomized clinical trial. A prediction model
was developed to estimate risk scores for failing OROS-MPH, where
treatment failure was deﬁned as less than 25% improvement in the
ADHD Rating Scale IV total score from baseline. Patients were ranked
by their predicted risks of OROS-MPH failure to deﬁne high-risk
subpopulations. Outcomes of LDX and OROS-MPH were compared
within subpopulations. Results: The prediction model for OROS-MPH
failure selected seven predictors (age, disease duration, and ﬁve ADHD
Rating Scale IV item scores) and had an in-sample C statistic of
0.860. Among all patients, LDX had a 17% (95% conﬁdence interval
7.1%–27.8%) lower treatment failure rate than that of OROS-MPH;ee front matter & 2015 Published by Elsevier Inc.
(ISPOR). This is an open access article under the
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ondence to: Juliana Setyawan, Global HEOR & Epidifferences in failure rates ranged from 17% to 43% across subpopu-
lations, increasingly enriched for high-risk patients. Similar hetero-
geneity across subgroups was observed for other efﬁcacy measures.
Conclusions: In the overall trial population, LDX was associated with
a lower rate of treatment failure compared with OROS-MPH in
patients with ADHD. A more pronounced beneﬁt of LDX over OROS-
MPH was observed among subpopulations with a higher predicted risk
of failing OROS-MPH. The present study showed the feasibility of
individualizing treatment selection. Future research is needed to
prospectively verify these results.
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The importance of treatment individualization in mental and
neurologic diseases has been widely recognized [1–4]. The evi-
dence available to inform individualized use of medication for
attention deﬁcit/hyperactivity disorder (ADHD), however, has
remained limited. Current treatment assignment is primarily
based on overall average treatment effects demonstrated in
clinical trials, experience of physicians or patients, safety con-
cerns, cost consideration, and patient/caregiver preferences [5–8].
To further optimize patient care in ADHD, evidence that can help
guide the selection of therapies in ADHD in clinical practice could
prove useful.
ADHD is a common neuropsychiatric disorder affecting 5.3%
of children and adolescents worldwide [9]. Lisdexamfetamine
dimesylate (LDX) and osmotic-release oral system methylpheni-
date (OROS-MPH) are two commonly used long-acting drugs for
ADHD from two classes of ﬁrst-line medication, amphetamine
and methylphenidate, respectively [10,11]. No published clinicaltrial has been speciﬁcally and prospectively designed to compare
the efﬁcacy of OROS-MPH and LDX. A phase III clinical trial
SPD489-325 (NCT00763971) aimed to evaluate the efﬁcacy and
safety of LDX in comparison with placebo and included an OROS-
MPH arm; however, the comparison of LDX and OROS-MPH was
not prespeciﬁed in the trial protocol. A post hoc analysis showed
that LDX, on average, was associated with superior efﬁcacy
compared with OROS-MPH in terms of improvements in ADHD
Rating Scale IV (ADHD-RS-IV) total score and the proportion of
patients showing clinical improvements, deﬁned by changes in
ADHD-RS-IV total score from baseline exceeding a certain thresh-
old and/or Clinical Global Impressions-Global Improvement (CGI-I)
score [12,13]. The post hoc analysis, however, did not evaluate
whether the beneﬁt of LDX versus OROS-MPH was consistent or
heterogeneous across different patient subgroups. It is our hypo-
thesis that the beneﬁt of LDX versus OROS-MPH could be hetero-
geneous across patient subgroups.
Heterogeneity in patients’ responses to different therapies
calls for individualized treatment selection. Pharmacogenetics, ason behalf of International Society for Pharmacoeconomics and
CC BY-NC-ND license
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ment selection, holds great promise with the advancement of
biotechnology. In the near term, however, the clinical application
of pharmacogenetics in ADHD could be limited because consis-
tent evidence linking genotypes to phenotypic responses to
ADHD treatments is still lacking [14–17]. Well-validated models
predicting treatment efﬁcacy using readily available patient and
disease characteristics can potentially provide a timely and
practical approach to individualize treatment selection in future
clinical practice.
The present study developed a predictive model for the risk of
failing OROS-MPH. Risk scores derived from this model were used
to classify patients into subgroups. Among these subgroups,
responses to LDX and OROS-MPH were compared to assess
whether the difference of LDX and OROS-MPH varied across
patient subgroups. The risk scores could potentially be used to
individualize treatment selection between LDX and OROS-MPH in
children and adolescents with ADHD [18,19].Methods
Study Population
The present study was a post hoc analysis of the SPD489-325 trial
(NCT00763971), which was a phase III, randomized, double-blind,
multicenter, placebo- and active-controlled study conducted
across Europe. A detailed description of the trial can be found
elsewhere [12]. In brief, the trial included children and adoles-
cents (aged 6–17 years) with an ADHD diagnosis, based on the
Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition,
Text Revision) criteria of ADHD. Eligible patients had ADHD of at
least moderate severity (baseline ADHD-RS-IV total score ofZ28).
A total of 336 subjects were randomized at the 1:1:1 ratio to be
subsequently treated for 7 weeks with LDX, OROS-MPH, or
placebo. Patients randomized to LDX or OROS-MPH who received
at least one dose of the investigational product were included in
the current analyses.Study Measures
Data on demographic characteristics, weight, height, body mass
index, disease characteristics, and previous ADHD treatment
were collected at baseline. For the current analyses, the outcome
variables were evaluated at week 7 and included 1) Treatment
failure: deﬁned as less than 25% improvement in ADHD-RS-IV
total score from baseline; 2) Treatment response: deﬁned as 25% or
more improvement in ADHD-RS-IV total score from baseline, that
is, opposite of treatment failure (alternative deﬁnitions using
Z30% and Z50% improvement cutoffs were considered in sensi-
tivity analyses); 3) Change in ADHD-RS-IV score (total score,
hyperactivity/impulsivity and inattentiveness subscale scores);
4) CGI-I response (achieving CGI-I of either “very much improved”
or “much improved”); 5) Composite response (Z30% improve-
ment in ADHD-RS-IV total score from baseline and achieving CGI-I
response); 6) Change in health-related quality of life measured
by Child Health and Illness Proﬁle-Child Edition: Parent Report
Form (CHIP-CE: PRF), (global T scores and domain scores); and 7)
Change in functional impairment measured withWeiss Functional
Impairment Rating Scale-Parent Report (WFIRS-P) (global scores
and domain scores). Treatment failure is deﬁned as less than
25% improvement in ADHD-RS-IV total score from baseline in
the present study because the 25% cutoff is widely used in the
ADHD literature, and at least 25% improvement is considered a
clinically detectable response to treatment in patients with ADHD
[20–27].Descriptions of Baseline Characteristics and Efﬁcacy of LDX
and OROS-MPH in the Overall Population
Patients’ baseline characteristics and efﬁcacy outcomes at week 7
were summarized for both LDX and OROS-MPH arms. Means and
SDs were calculated for continuous variables, and counts and
proportions were calculated for categorical variables. For efﬁcacy
outcomes at week 7, differences in means of continuous variables
between the two treatment arms were compared using two-
sample t tests, and differences in categorical variables were
compared using chi-square tests (or Fisher exact test if Z25% of
the cells had expected counts o5). The last observation carried
forward method was used to impute the efﬁcacy outcomes at
week 7 by carrying forward the last available postbaseline
measure to week 7 when there were missing values.
Development of a Prediction Model for Risk of Failing
OROS-MPH
A logistic regression model was ﬁt using the data of all OROS-
MPH patients in the study sample to predict failure to OROS-MPH.
A least absolute shrinkage and selection operator (LASSO)
approach was applied to select an optimal set of covariates from
a list of candidate covariates [28]. Instead of selecting one
covariate at a time or predeﬁning a list of covariates, the LASSO
method allowed simultaneous selection of a set of variables
predictive of OROS-MPH treatment failure. The list of candidate
covariates considered included age, sex, race, body mass index,
ADHD subtype, disease duration, comorbidities, previous ADHD
pharmacologic and behavioral treatment, and disease severity
measured by ADHD-RS-IV item scores. The C statistic and the
Hosmer-Lemeshow statistic were computed to evaluate the ﬁt of
the model.
Attempt was also made to develop a prediction model for the
risk of failing LDX; however, because of the limited heterogeneity
in the treatment failure rate to LDX (i.e., the low failure rate of
9.2% among LDX-treated patients), an intercept-only model was
obtained, which was not suitable for individualizing treatment
selection.
Comparison of Efﬁcacy Outcomes across Patient Subgroups
Differences in efﬁcacy outcomes between LDX and OROS-MPH
across patient subgroups were depicted using treatment differ-
ence curves. On these curves, differences in the observed rates of
treatment failure to LDX and OROS-MPH were plotted (Y-axis) by
subpopulations increasingly enriched for patients with high risk
to fail OROS-MPH (X-axis). Randomized Monte-Carlo cross-vali-
dation was used to construct such curves. Speciﬁcally, patients in
the study sample were randomly split to training (60% of OROS-
MPH–treated patients) and validation (40% of OROS-MPH–treated
patients and all LDX-treated patients) samples. A logistic regres-
sion model, using the covariates selected by the LASSO approach,
was ﬁt to the training sample; the ﬁtted model was applied to the
validation sample to obtain patients’ risk scores of failing OROS-
MPH. Patients were ranked by their risk scores and were sequen-
tially grouped together by 10% increments, starting from the top
30% of patients with the highest risk scores (this cutoff was
selected because of the sample size: there are o10 OROS-MPH
patients if the 20% threshold is used), until all patients (100%)
were included. The subpopulation size and the respective risk
score thresholds to form the subpopulation were both provided
on the X-axis. Within each of these cumulative subgroups, the
actual observed rates of treatment failure to LDX and OROS-MPH
and the difference in these observed rates were calculated, and
the average rates across the 2000 iterations in the randomized
Monte-Carlo cross-validation were used for plotting. Bootstrap-
ping was used to create the 95% conﬁdence interval (CI) for the
Table 1 – Baseline characteristics.*
Baseline characteristic LDX
(N ¼ 104)
OROS-MPH
(N ¼ 107)
Age (y), mean  SD 10.8  2.8 10.7  2.6
Sex: male, n (%) 81 (77.9) 86 (80.4)
White, n (%) 101 (97.1) 103 (96.3)
ADHD subtype, n (%)
Predominantly inattentive 22 (21.2) 13 (12.3)
Predominantly hyperactive-
impulsive
2 (1.9) 1 (0.9)
Combined 80 (76.9) 92 (86.8)
Disease duration (mo), mean 
SD
27.7  33.7 26.2  30.0
Comorbidities, n (%)
Psychiatric condition 4 (3.8) 6 (5.6)
Neurologic condition 12 (11.5) 8 (7.5)
Previous ADHD treatment,
n (%)
Pharmacologic 57 (54.8) 58 (54.2)
Behavioral 30 (28.8) 30 (28.0)
Baseline disease severity†
ADHD-RS-IV total score, mean
 SD
40.7  7.3 40.5  6.7
Baseline health-related quality-
of-life assessment‡
CHIP-CE: PRF at baseline,
mean  SD
30.6  12.4 29.8  10.2
Baseline functional assessment§
WFIRS-P at baseline, mean 
SD
1.0  0.5 1.1  0.4
ADHD, attention deﬁcit/hyperactivity disorder; ADHD-RS-IV,
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MPH) in treatment failure rates was compared between each
cumulative patient subgroup and the rest of the patients
to evaluate whether the difference in the identiﬁed subgroup
was signiﬁcantly different from the difference in the overall
population.
In addition to treatment failure rates, other treatment out-
comes were evaluated using treatment difference curves, includ-
ing ADHD-RS-IV score change from baseline, treatment response,
CGI-I response, composite response, CHIP-CE: PRF change from
baseline, and WFIRS-P score change from baseline.
Description of Baseline Characteristics and Treatment
Outcomes for Patient Subgroups
To describe how risk scores of failing OROS-MPH could poten-
tially be used to identify patients with high risk of failing OROS-
MPH in clinical practice and to provide a proﬁle description of
patients for whom the beneﬁt of LDX over OROS-MPH was more
pronounced, all patients in the study sample were ranked and
stratiﬁed into three mutually exclusive subgroups on the basis of
tertiles of the estimated risk scores of OROS-MPH failure. The
tertiles were selected in the present study for illustration purpose
only; in clinical practice, the cutoffs could be chosen on the basis
of clinically meaningful values. These subgroups were labeled
“low,” “medium,” and “high” risk of treatment failure to OROS-
MPH. Baseline characteristics and treatment outcomes were
summarized for LDX- and OROS-MPH–treated patients within
each subgroup, and pairwise comparisons were conducted
between the three subgroups.
Patient descriptive summaries were performed using SAS 9.3
(SAS Institute, Inc., Cary, NC). All other analyses were performed
using R version 3.0.1 (http://cran.r-project.org).ADHD Rating Scale IV; CHIP-CE: PRF, Child Health and Illness
Proﬁle-Child Edition: Parent Report Form; LDX, lisdexamfetamine
dimesylate; OROS-MPH, osmotic-release oral system methylphe-
nidate; WFIRS-P, Weiss Functional Impairment Rating Scale -
Parent Report.
* Observed values were used for baseline characteristics.
† Higher scores in ADHD-RS-IV indicated worse ADHD symptoms.
‡ Higher CHIP-CE: PRF Global T score indicated better health
conditions.
§ Lower WFIRS-P Global score indicated better functional outcome.Results
Baseline Characteristics
A total of 211 patients were included in the analysis, with 104
receiving LDX and 107 receiving OROS-MPH. Baseline character-
istics were well balanced between the LDX and OROS-MPH arms
(Table 1). The mean age was 10.8 years for the LDX arm and 10.7
years for the OROS-MPH arm. Most of the patients were male
(77.9% for the LDX arm vs. 80.4% for the OROS-MPH arm) and
white (97.1% vs. 96.3%). Most of the patients were diagnosed with
the combined ADHD subtype (76.9% vs. 86.8%). The disease had
lasted over 2 years on average at the time of enrollment into the
trial (27.7 vs. 26.2 months). More than half of the patients had
previous pharmacologic treatment for ADHD (54.8% vs. 54.2%).
ADHD-RS-IV total score at baseline was similar across arms.
Health-related quality of life and functional assessment at base-
line were also comparable across treatment arms.
Comparison of Efﬁcacy Outcomes in the Overall Population
Among all patients, LDX was associated with better efﬁcacy
outcomes at week 7 compared with OROS-MPH (Table 2). LDX-
treated patients achieved higher rates of treatment response
(90.8% vs. 73.8%; P ¼ 0.0016). The difference in treatment
response remained signiﬁcant in sensitivity analyses using a
threshold of achieving an improvement of 30% or more (88.8%
vs. 70.9%; P ¼ 0.0016) and 50% or more (69.4% vs. 51.5%; P ¼
0.0094) in ADHD-RS-IV total score from baseline. LDX-treated
patients also achieved higher rates of CGI-I response (78.0% vs.
60.6%; P ¼ 0.0071) and composite response (74.2% vs. 55.9%, P ¼
0.0068) than did OROS-MPH–treated patients, and experienced
greater improvements in symptoms as measured by the changein ADHD-RS-IV total score from baseline (mean –24.7 vs. –18.9;
P ¼ 0.0005). Compared with patients receiving OROS-MPH,
patients receiving LDX showed numerically larger reductions in
functional impairment—measured by WFIRS-P change from base-
line—and better improvement in health-related quality of life—
measured by CHIP-CE: PRF—though these differences were not
statistically signiﬁcant. Signiﬁcantly larger improvement, how-
ever, was observed in the achievement domain within CHIP-CE:
PRF (9.1 vs. 5.9; P ¼ 0.0333) on comparing LDX to OROS-MPH.
Development of a Model Estimating Risk Scores for Failing
OROS-MPH
Seven baseline characteristics—age, disease duration, and ﬁve
individual items measured by the ADHD-RS-IV instrument—were
selected for inclusion by the LASSO method into a model
predicting risk scores for failing OROS-MPH (Table 3). Among
the selected covariates, older age (odds ratio 1.19 per year) and
longer disease duration (odds ratio 1.02 per month) were
associated with greater odds of treatment failure to OROS-MPH.
In addition, higher scores (i.e., greater symptom severity) for
ADHD-RS-IV items 2 (“Fidgets with hands or feet or squirms”), 10
Table 2 – Treatment outcomes at week 7.
Outcome measures LDX (N ¼ 104) OROS-MPH (N ¼ 107) P value
Efﬁcacy outcomes at week 7, LOCF*
Response to treatment (Z25% improvement in ADHD-RS-IV score), n (%)
Yes 89 (90.8) 76 (73.8) 0.0016†
No 9 (9.2) 27 (26.2)
Response to treatment (Z30% improvement in ADHD-RS-IV score), n (%)
Yes 87 (88.8) 73 (70.9) 0.0016†
No 11 (11.2) 30 (29.1)
Response to treatment (Z50% improvement in ADHD-RS-IV score), n (%)
Yes 68 (69.4) 53 (51.5) 0.0094†
No 30 (30.6) 50 (48.5)
ADHD-RS-IV score change from baseline, mean  SD
Total score change –24.7  10.2 –18.9  12.9 0.0005‡
Hyperactivity/impulsivity subscale score change –11.2  5.5 –8.7  6.9 0.0044†
Inattentiveness subscale score change –13.5  6.3 –10.3  7.0 0.0008‡
CGI-I response, n (%)
Yes 78 (78.0) 63 (60.6) 0.0071†
No 22 (22.0) 41 (39.4)
Composite response, n (%)
Yes 72 (74.2) 57 (55.9) 0.0068†
No 25 (25.8) 45 (44.1)
Health-related quality-of-life outcome at week 7, LOCF*
CHIP-CE: PRF change from baseline, mean  SD 8.4  9.5 7.1  9.3 0.4147
Functional outcome at week 7, LOCF†
WFIRS-P change from baseline, mean  SD 0.3  0.4 0.3  0.3 0.5675
ADHD, attention deﬁcit/hyperactivity disorder; ADHD-RS-IV, ADHD Rating Scale IV; CGI-I, Clinical Global Impression – Global Improvement;
CHIP-CE: PRF, Child Health and Illness Proﬁle-Child Edition: Parent Report Form; LDX, lisdexamfetamine dimesylate; LOCF, last observation
carried forward; OROS-MPH, osmotic-release oral system methylphenidate; WFIRS-P, Weiss Functional Impairment Rating Scale - Parent Report.
* For each outcome, summary statistics were calculated only among patients with nonmissing values after LOCF.
† P o 0.01.
‡ P o 0.001.
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excessively”), and 13 (“Loses things necessary for tasks or activ-
ities”) at baseline were positively associated with treatment
failure, whereas item 9 (“Has difﬁculty organizing tasks and
activities”) was inversely associated with treatment failure. This
model had an in-sample C statistic of 0.860, which suggested
good in-sample discrimination and adequacy of genuine clinical
utility [29]. The in-sample Hosmer-Lemeshow P value was 0.191,
indicating an adequate ﬁt of the model to the study data.Comparison of Efﬁcacy Outcomes across Patient Subgroups
Figure 1 shows the treatment difference curves between LDX-
treated patients and OROS-MPH–treated patients, with nonmiss-
ing values for the seven covariates selected in the prediction
model and nonmissing value for treatment failure outcome. The
treatment difference curve showed substantial heterogeneity in
the difference in treatment failure rates between LDX and OROS-
MPH across cumulative patient subgroups (Fig. 1A). In the top 30%
of the population (i.e., patients with predicted risk scores of
failing OROS-MPH of Z0.42), LDX-treated patients demonstrated
a lower rate of treatment failure (95% CI) by 43.4% (19.2%–67.7%)
than did those treated with OROS-MPH. As more patients with
lower risk of failing OROS-MPH were included, the difference
between LDX-treated and OROS-MPH–treated patients decreased.
If all patients were included (i.e., 100% of the validation sample),
LDX-treated patients achieved a 17.5% (95% CI 7.1%–27.8%) lower
rate of treatment failure than did OROS-MPH–treated patients.
The difference (LDX vs. OROS-MPH) in the 30%, 40%, 50%, and 60%
patient subgroups (i.e., subgroups of patients with predicted risk
scores of Z0.42, 0.27, 0.15, and 0.08, respectively) weresigniﬁcantly different from those observed in the overall popula-
tion (P ¼ 0.0071, 0.0059, 0.0089, 0.0306, respectively). The treat-
ment failure curve plotted by treatment arms indicated that the
substantial heterogeneity in the difference in treatment failure
rates between LDX and OROS-MPH across patient subgroups was
due to variability in the observed treatment failure rate to OROS-
MPH across subgroups, with a higher OROS-MPH treatment fail-
ure rate in the subgroup with high risk scores of failing OROS-
MPH, and the failure rate decreased when more patients were
included (Fig. 1B). In contrast, there was a constant and relatively
low treatment failure rate to LDX observed across all subgroups.
Similar trends were observed when comparing treatment
response to LDX and OROS-MPH and its sensitivity measures,
where LDX indicated a more pronounced beneﬁt of use among
the subgroup of patients with high risk scores of failing OROS-
MPH (data not shown).
In comparing the effectiveness of LDX to OROS-MPH treat-
ment for ADHD, substantial heterogeneity was also observed in
ADHD-RS-IV absolute total score change from baseline. LDX-
treated patients achieved greater reduction in ADHD-RS-IV abso-
lute total score: 10.7 (95% CI 3.3–18.2) in the top 30% subgroup, 9.1
(95% CI 3.7–14.6) in the top 50% subgroup, and 5.7 (95% CI 2.5–8.9)
in the 100% of sample compared with OROS-MPH–treated
patients (Fig. 2). Similar trends were observed in ADHD-RS-IV
hyperactivity/impulsivity and inattentiveness subscale scores,
CGI-I response, and composite response, with the beneﬁt being
more pronounced in the top 30% to 50% subgroup than in
the overall population (see Figs. E1–E4 in Supplemental Mater-
ials found at http://dx.doi.org/10.1016/j.jval.2015.06.005). For all
these outcomes, statistical signiﬁcance was maintained across all
subgroups evaluated. In terms of the functional impairment
Table 3 – Predictive model for treatment failure to
OROS-MPH.*
Model parameters Estimate Odds
ratio
Intercept –6.26 –
Age (y) 0.18 1.19
Disease duration (mo) 0.02 1.02
ADHD RS-IV item score - hyperactivity
2. Fidgets with hands or feet or squirms 0.44 1.56
10. Is “on the go” or acts as if “driven by
a motor”
0.20 1.22
12. Talks excessively 0.80 2.23
ADHD-RS-IV item score - inattentive
9. Has difﬁculty organizing tasks and
activities
–0.14 0.87
13. Loses things necessary for tasks or
activities
0.12 1.12
Model diagnostic statistics
(In-sample)
Estimate P
value
C statistic/AUC 0.860 –
Hosmer–Lemeshow 11.187 0.191
ADHD-RS-IV, Attention Deﬁcit Hyperactivity Disorder Rating Scale
IV; AUC, area under the curve; OROS-MPH, osmotic-release oral
system methylphenidate.
* Predictive model for treatment failure to OROS-MPH was
developed using the least absolute shrinkage and selection
operator method in the full data of OROS-MPH patients for
whom all baseline covariates and the outcome data were
available (N ¼ 101).
Fig. 1 – Cross-validated treatment difference curves for
treatment failure rates at week 7* showing (A) treatment
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measured by CHIP-CE: PRF, similar trends of heterogeneity
persisted, with consistently numerically better outcome of LDX
compared with OROS-MPH, and with signiﬁcant differences
observed in the CHIP-CE: PRF achievement domain scores (see
Figs. E5–E7 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2015.06.005).difference between LDX and OROS-MPH and (B) treatment
effect among LDX and OROS-MPH. LDX, lisdexamfetamine
dimesylate; OROS-MPH, osmotic-release oral system
methylphenidate. *Population size referred to the proportion
of patients in the validation sample included in the
subgroup on the basis of their predicted probabilities of
treatment failure to OROS-MPH (patients with the highest
probabilities of treatment failure to OROS-MPH were ranked
the highest and included ﬁrst).Description of Baseline Characteristics and Treatment
Outcomes for Patient Subgroups
Risk scores of OROS-MPH failure could potentially be used to
identify patients most likely to beneﬁt even more from LDX than
from OROS-MPH, compared with the beneﬁt observed in the
overall population. As an illustration, patients were stratiﬁed
into “high” (N ¼ 66), “medium” (N ¼ 67), and “low” (N ¼ 67) risk
subgroups on the basis of tertiles of their risk scores of failing
OROS-MPH (see Table E1 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.06.005). Patients in the “high”
risk subgroup tended to be older and had signiﬁcantly longer
disease duration than did patients in the “medium” or “low” risk
subgroups. Patients in the “high” risk subgroup also tended to
score higher on ADHD-RS-IV items 2, 10, and 12. In addition,
patients in the “high” risk subgroup tended to score signiﬁcantly
higher on most of the other ADHD-RS-IV hyperactivity/impulsiv-
ity item scores but did not score signiﬁcantly higher on the
inattentiveness subscale item scores. The “high” risk subgroup,
compared with the “medium” and “low” risk subgroups, was also
more likely to be classiﬁed as having the combined ADHD subtype
and having taken prior pharmacologic treatment for ADHD.
The treatment outcomes comparing LDX and OROS-MPH
were evaluated within and between risk subgroups deﬁned by
estimated risk scores of OROS-MPH failure (see Table E2 inSupplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.06.005). Consistent with the trends suggested by treatment
difference curves, OROS-MPH–treated patients had worse treat-
ment effects in the “high” risk subgroup than in the other two
subgroups, while LDX-treated patients maintained relatively
consistent treatment effects across risk subgroups. The greatest
difference in treatment effects of LDX and OROS-MPH resided in
the “high” risk subgroup. The difference between LDX and OROS-
MPH on treatment response deﬁned by 25% or more improve-
ment in ADHD-RS-IV total score was 41.1% (P ¼ 0.001) among the
“high” risk subgroup and 6.6% (P ¼ 0.233) and 5.9% (P ¼ 0.525),
respectively, in the “low” and “medium” risk subgroups. Similar
trends were observed in other treatment outcomes, with larger
and statistically signiﬁcant differences between LDX and OROS-
MPH observed among the “high” risk subgroup, while smaller,
numerically better but not statistically signiﬁcant beneﬁts of LDX
Fig. 2 – Cross-validated treatment difference curves for
ADHD-RS-IV total score changes from baseline at week 7*
showing (A) treatment difference between LDX and OROS-
MPH and (B) treatment effect among LDX and OROS-MPH.
ADHD-RS-IV, attention deﬁcit/hyperactivity disorder Rating
Scale IV; LDX, lisdexamfetamine dimesylate; OROS-MPH,
osmotic-release oral system methylphenidate. *Population
size referred to the proportion of patients in the validation
sample included in the subgroup on the basis of their
predicted probabilities of treatment failure to OROS-MPH.
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subgroups. Differences in LDX versus OROS-MPH in the “high”
risk subgroup are signiﬁcantly different from differences
observed in the “medium” and “low” risk subgroups for treatment
responses deﬁned by 25% or more and 30% or more improvement
in ADHD-RS-IV total score.Discussion
The present study evaluated the potential to predict treatment
failure of OROS-MPH, and to use a risk score to individualize
treatment with LDX versus OROS-MPH in patients with ADHD.
Using phase III clinical trial data, we were able to construct a model
to score patients’ risks of failing OROS-MPH on the basis of patient
and disease characteristics. On the basis of risk scores of OROS-MPH
failure, patient subgroups were identiﬁed where the clinical beneﬁtof LDX versus OROS-MPH was more pronounced than the average
beneﬁt of LDX versus OROS-MPH observed in the overall population.
A similar ﬁnding was observed in a previous analysis using US
administrative claims data [30], in which a larger difference in the
rates of switching/augmentation (a proxy measure for suboptimal
response) between LDX and OROS-MPH was observed among sub-
groups of patients with high risk of switching/augmentation with
OROS-MPH than the difference observed in the overall population.
Patients have varied responses to different therapies, in terms
of both efﬁcacy and safety, which is determined by their unique
patient and disease characteristics, variation in genetic compo-
sition, and environmental factors [31,32]. Ideally, treatments
should be individualized to achieve maximal response rates
and minimize the occurrence of adverse events. In recent years,
the concept of personalized medicine has become a major focus
of comparative effectiveness research, which was traditionally
focused on comparing average responses between treatments in
the overall population [33]. Recently, health technology assess-
ment authorities such as the National Institute for Health and
Care Excellence have published guidelines regarding how sub-
groups should be considered for both clinical efﬁcacy and cost-
effectiveness to maximize the health gains by optimizing treat-
ment selection [34]. This is an essential step toward individu-
alized treatment selection. In addition to analyses of predeﬁned
subgroups, several recently published studies have developed
statistical methodology, including the personalized treatment
selection method used in the present study, to systematically
identify subgroups of patients in whom treatment assignment
can be optimized on the basis of individual characteristics [18,19].
The importance of treatment individualization in mental
health and neurological diseases is reﬂected by more than 20
years of research on the use of pharmacogenetics to guide
treatment selection, as well as by different attempts to develop
prediction algorithms for treatment efﬁcacy on the basis of
readily available patient and disease characteristics instead of
genetic information [1–4]. For example, Johnson et al. [35] pre-
sented initial evidence that a combined ﬁve-marker genotype
panel was associated with treatment outcome to alcohol depend-
ence with ondansetron. Ising et al. [36] discovered a number of
genetic factors combined with clinical features that could be used
to predict antidepressant drug treatment outcome. Alternatively,
the endeavor of treatment individualization has also witnessed
studies focused on individualization by patient and disease
characteristics. For example, Buitelaar et al. [3] conducted a post
hoc analysis of a clinical trial for adult patients with ADHD and
suggested that higher Conners’ Adult ADHD Rating Scale score,
male sex, and lower academic achievement were predictive of
improved results with OROS-MPH treatment. Compton et al. [37]
and Manglick et al. [38] have also found patient and disease
characteristics as predictors of treatment response in childhood
anxiety disorders and depression, respectively.
In the present study, by using the personalized treatment
selection approach, we observed high variability in patients’
clinical responses to OROS-MPH across patient subgroups that
were deﬁned by risk scores of OROS-MPH failure. Among patients
with high risk potential for failing OROS-MPH (high risk scores),
the beneﬁt of LDX over OROS-MPH was more pronounced than
that observed in the overall population. Such a ﬁnding was
consistently observed with multiple efﬁcacy measures, including
treatment response measures, change in ADHD-RS-IV score from
baseline, CGI-I response, and composite response. When analyz-
ing the functional impairment measure WFIRS-P and the quality-
of-life measure CHIP-CE: PRF, LDX was observed to be associated
with numerically better improvements than was OROS-MPH, but
statistical signiﬁcance was observed only when comparing LDX
and OROS-MPH on the CHIP-CE: PRF achievement domain. LDX
showed only numerically higher total score on CHIP-CE: PRF and
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from the fact that the study was limited by small sample size and
was not powered to detect signiﬁcant difference in WFIRS-P and
CHIP-CE: PRF between LDX and OROS-MPH. A study with larger
sample size is needed to further evaluate whether there is a
differential impact between these two treatments on quality of
life and functional measures.
The present study provides valuable information for making
treatment selection between OROS-MPH and LDX in patients with
ADHD. The results suggest that the use of currently available
generic OROS-MPH instead of LDX could potentially save drug
costs, yet at the expense of decreased efﬁcacy, which is especially
a concern among patients who have a higher chance of failing
OROS-MPH, among whom the clinical beneﬁt of LDX over OROS-
MPH is even more pronounced than average. These patients were
characterized in our study by older age, longer disease duration,
and higher scores on several hyperactivity or inattentiveness
items measured in ADHD-RS-IV. The results suggest that the
trade-off between beneﬁts and costs of using different treatments
should be carefully considered and individualized for patients,
and future studies evaluating the cost-effectiveness of LDX and
OROS-MPH by patient subgroups should be explored.
The ﬁndings of the present study suggest that individualized
treatment selection based on patient and disease characteristics
is feasible in the treatment of ADHD. Planning treatment on the
basis of an established predictive model that considers individual
characteristics as opposed to relying on average treatment effects
is expected to improve the ability of tailoring ADHD therapy, and
reducing the possibility for patients to experience suboptimal
care. Clinical trials guided by treatment individualization algo-
rithms can be designed in the future to help determine the merits
of personalized treatment selection in ADHD treatment. In terms
of real-world application, an index card or an online tool could be
developed to calculate the risk of failing OROS-MPH for a given
patient, in order to customize therapy selection.
In the present study, we developed a prediction model for
estimating risk scores for failing OROS-MPH. The mean predicted
and observed OROS-MPH failure rates were fairly close (see Fig. E8
in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.06.005), with the predicted scores tending to be numerically
higher than the observed failure rates. Alternatively, we could
develop a prediction model for estimating risk scores for failing
LDX. We have not, however, been able to generate such a model
because of the lack of variability in LDX-treated patients’ responses.
Among LDX-treated patients, 90.8% of the patients responded to
treatment, with less than 10% having treatment failure. Such small
heterogeneity among LDX-treated patients led to an intercept-only
model, which has prevented us from constructing a model to
stratify patients on the basis of their response to LDX.
The prediction model developed in the present study has been
evaluated for treatment individualization only between LDX and
OROS-MPH. The prediction model, however, could potentially be
used to individualize treatment decisions between OROS-MPH and
other pharmacological therapies; before such application, validation
is warranted to evaluate whether the estimated risk scores can
effectively stratify patients into subgroups with differential differ-
ences in treatment effects of OROS-MPH and other therapies.
There are several limitations of this study. First, the data used
here were from a clinical trial population with speciﬁc patient
selection criteria, which may not be generalizable to the broader
ADHD population. Second, the sample size in the present study is
relatively small, such that a traditional holdout validation
procedure to construct the treatment difference curves—where
the entire data are split into independent training and validation
samples—could not be conducted. Instead of using hold-
out validation, randomized Monte-Carlo cross-validation was
implemented to construct the treatment difference curves. Thisapproach allows the full utilization of study sample, while still
training and validating the model in separate data sets. In
addition, patients were stratiﬁed into three subgroups to illus-
trate the potential of using risk scores of OROS-MPH failure to
identify subgroups of patients with more pronounced beneﬁt
from LDX over OROS-MPH in the present study. This exercise is
for illustration purpose only, and, in clinical practice, the cutoff
values for selecting optimal subgroups should be based on
clinically meaningful values. Last, a last observation carried
forward approach was used to impute the missing data to be
consistent with the analytical approach used in the primary
analysis of the trial data [12]. Future analyses using other
imputation methods such as the model-based approach for
imputing missing data should be considered to validate the
present study results [39–47].
The present study has shown that individualized treatment
selection based on patient and disease characteristics is feasible,
which is an important step in advancing the ongoing compara-
tive effectiveness research efforts to improve patient care and to
support individualized treatment selection in patients with
ADHD. Future studies are desired to prospectively validate the
present study ﬁndings.Acknowledgments
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